Endo will pay up to $637M for Indevus
In a bid to break out of its pain therapy niche, Endo Pharmaceuticals agreed to pay up to $637 million to acquire Indevus Pharmaceuticals. Indevus shareholders get $370 million of that now and up to $267 million more if a series of discovery and commercial milestones are hit. Report |  |  |  |  |
Latest News
Also Noted
> Just days after pulling its IPO, Anacor Pharmaceuticals announced that it had raised $50 million through a preferred stock financing with participation from GlaxoSmithKline, Schering Corporation and existing investors, including Rho Capital Partners, Venrock Associates, Care Capital and Aberdare Ventures. Release
> Could Daiichi Sankyo be suffering from buyer's remorse? Yesterday, we noted that the Japanese drugmaker was already taking a writedown on its buyout of India's Ranbaxy Laboratories. A $3.8 billion writedown, to be specific. Now, more details are emerging. Report
> Lexington, MA-based Cubist Pharmaceuticals has arranged a $90 million line of credit with the Royal Bank of Canada. Cubist also filed two IND applications. Report
Read more >>Latest Comments
- I am a retired Hospital Rep. with 35 years ex...
- I think advising against "too many press rele...
- Why not take a smaller flier into biotech and...
- It would be instructive to know what percent ...
- I hear that Anacor is going to be a great com...
- In case it isn't clear, that was a joke. (y...
- Catbell7, your assumptions are so ignorant. C...
Feature
FierceBiotech's most popular stories of 2008
With 2008 behind us, we'd like to take a look back at the stories and special reports our readers found most interesting over the past year. Unlike the 2007 list, which was dominated by Pfizer news, 2008's top stories covered a mixed bag of topics, ranging from breakthroughs at ACT and Follica to the ongoing financial problems plaguing the biotech industry. ArticleEmerging Drug Developer
Synta Pharmaceuticals
The folks at Synta Pharmaceuticals know how to end a year with a bang. While most people were preparing for the Christmas and New Year's holiday bash, Synta was finalizing a development deal worth potentially $1 billion with Roche. Significantly, the deal covers some of its preclinical work and will include up to three compounds targeting calcium release-activated calcium modulator channels aimed at inflammatory diseases. ArticleReport
Roche, Synta ink $1B deal
Lexington, MA-based Synta Pharmaceuticals and Roche have signed a licensing deal for preclinical anti-inflammatory compound, according to an SEC filing. Synta gets $25 million up front and up to $1 billion in milestone payments if the drug makes it to market. ArticlePress Releases
- CellCentric and Takeda Collaborate on Epigenetic Programme
- Court Rules in Favor of Medtronic in Fidelis Litigation
- Advaxis' Phase II Clinical Trial "HOLD" Lifted
- G. Steven Burrill predicts what's ahead for biotech in 2009
- Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals
- Grape-seed extract kills laboratory leukemia cells, proving value of natural compounds
